Global Diabetes Market Research and Forecast, 2018-2023

  • ID: 3821046
  • Report
  • Region: Global
  • Orion Market Research Private Limited
15 % OFF
until Sep 30th 2018
1 of 5

FEATURED COMPANIES

  • Abbott Laboratories Inc
  • Biocon Ltd.
  • Diamyd Medical
  • Johnson And Johnson
  • Medtronic Plc
  • Novo-Nordisk
  • MORE
Global diabetes market is expected to grow at a CAGR of 7.6% percent for the forecasted period of 2018-2023. The market is segmented on the basis of type of diabetes, drugs class and diabetic devices. Diabetic drugs have the highest market share amongst drugs and devices and are also expected to have the highest growth rate with a CAGR of 8.9%. Some of the top selling diabetic drugs include Lantus (Sanofi), Januvia (Merck And Co), Humalog (Eli Lily And Co), Novorapid (Novo Nordisk), Levemir (Novo Nordisk), Victoza (Novo Nordisk), Janumet (Merck And Co.), Novolog (Novo Nordisk), Humalin (Eli Lily And Co.) And Galvus (Novartis). With the diabetic population expected to cross the 350 million market by 2030 the market is expected to show strong growth rate. Diabetic drugs are highly priced which could be one of the major drawbacks.

Diabetic devices includes blood glucose meters and insulin delivery devices. The market for blood glucose meters will have the highest market share compared to the insulin delivery systems such as syringes and injection pens. Continuous glucose monitoring systems will have the highest market growth. Meter and strips are expected to dominate the overall market share in diabetic devices.

Overall the market is driven by growing burden of diabetes on economies. U.S. alone spends 11% of its health expenditure on diabetes. India and China are most affected by diabetes with over 120 million patients. A majority of diabetes patients are either undiagnosed or lack the basic treatment. The impending unmet needs are forcing the companies and governments to provide basic needs for diabetes. Research and development is ongoing to development long term solution for diabetes. Some of the leading manufacturers are trying to develop artificial pancreas. Currently CGMS devices are being used with insulin pumps as secondary prototype for artificial pancreas. It is expected that artificial pancreas will be ready for commercialization by next decade. Development of artificial pancreas has gained support from USFDA, which is a major boost for the market.

North America is the leading geography followed by Europe and Asia Pacific. Asia Pacific is expected to have the highest growth rate amongst the regions. North American market is driven by high awareness, availability of reimbursements and high expenditure on healthcare. Asia Pacific market is driven by high population of diabetic patients.

The report provides detailed & insightful chapters which include market overview, key findings, strategic recommendations, market estimations, patent analysis, pipeline analysis, market determinants, key company analysis, company profiling, market segmentation, geographical analysis, analyst insights and predictive analysis of the market.

Market Segments Included in the Report:

Diabetes by Type
Type 1 Diabetes
Type 2 Diabetes
Gestational Diabetes
Drug Class
Alpha-Glucosidase Inhibitors
Amylin Analogs
Antidiabetic Combinations
Dipeptidyl Peptidase 4 Inhibitors
Incretin Mimetics
Insulin
Meglitinides
Non-Sulfonylureas
Sglt-2 Inhibitors
Sulfonylureas
Thiazolidinediones
Diabetic Devices
Blood Glucose Meters
Blood Glucose Strips
Insulin Injection Pens
Insulin Syringes
Continuous Glucose Monitoring Systems
Insulin Pumps
Lancets

The Report Covers:

Comprehensive research methodology of Diabetes market
In-depth analysis of macro and micro factors influencing the market guided by key recommendations.
Analysis of regional regulations and other government policies impacting the global Diabetes market
Insights about market determinants which are stimulating the global Diabetes market
Detailed and extensive market segments with regional distribution of forecasted revenues
Extensive profiles and recent developments of market players
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Abbott Laboratories Inc
  • Biocon Ltd.
  • Diamyd Medical
  • Johnson And Johnson
  • Medtronic Plc
  • Novo-Nordisk
  • MORE

1. Report Summary
1.1. Research Methods And Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
1.2.3. By Stakeholders

2. Market Overview And Insights
2.1. Definition
2.2. Pipeline Analysis
2.3. Analyst Insights & Current Market Trends
2.3.1. Key Findings
2.3.2. Recommendation
2.3.3. Conclusion
2.4. Regulations
2.4.1. Tax Laws
2.4.1.1. United States
2.4.1.2. European Union
2.4.1.3. China
2.4.1.4. India
2.4.1.5. Rest Of The World
2.4.2. Drug And Device Regulations
2.4.2.1. United States
2.4.2.2. European Union
2.4.2.3. China
2.4.2.4. India
2.4.2.5. Japan
2.4.3. Top Selling Diabetes Drugs
2.4.3.1. Lantus (Sanofi)
2.4.3.2. Januvia (Merck And Co)
2.4.3.3. Humalog (Eli Lily And Co)
2.4.3.4. Novorapid/Novolog (Novo Nordisk)
2.4.3.5. Levemir (Novo Nordisk)
2.4.3.6. Victoza (Novo Nordisk)
2.4.3.7. Janumet (Merck And Co.)
2.4.3.8. Humulin (Eli Lily And Co.)
2.4.3.9. Toujeo (Sanofi)

3. Market Determinant
3.1. Motivators
3.1.1. Growing Prevalence And Incidence Rate Of Diabetes
3.1.2. Innovations And Development Of New Products
3.1.3. Growing Popularity Of Wearable Devices And Poc Solutions
3.2. Restraints
3.2.1. Number Of Undiagnosed Patients In Developing Countries Is High
3.2.2. Cgms And Insulin Pumps Devices Sale Limited To Developed Market
3.2.3. High Price And Recurring Cost
3.3. Opportunities
3.3.1. Emerging Markets
3.3.2. Development Of Artificial Pancreases
3.3.3. Development Of Minimally Invasive And Non-Invasive Monitoring Devices

4. Market Segmentation
4.1. Diabetes Market By Type
4.1.1. Type 1 Diabetes
4.1.2. Type 2 Diabetes
4.1.3. Gestational
4.2. Diabetes Market By Drug Class
4.2.1. Alpha-Glucosidase Inhibitors
4.2.2. Amylin Analogs
4.2.3. Antidiabetic Combinations
4.2.4. Dipeptidyl Peptidase 4 Inhibitors
4.2.5. Incretin Mimetics
4.2.6. Insulin
4.2.7. Meglitinides
4.2.8. Non-Sulfonylureas
4.2.9. Sglt-2 Inhibitors
4.2.10. Sulfonylureas
4.2.11. Thiazolidinedione
4.3. Diabetes Market By Devices
4.3.1. Blood Glucose Meters
4.3.2. Blood Glucose Strips
4.3.3. Insulin Injection Pens
4.3.4. Insulin Syringes
4.3.5. Continuous Glucose Monitoring Systems
4.3.6. Insulin Pumps
4.3.7. Lancets

5. Competitive Landscape
5.1. Market Share Analysis
5.2. Key Company Analysis

6. Regional Analysis
6.1. North America
6.1.1. United States
6.1.2. Canada
6.1.3. Rest Of North America
6.2. Europe
6.2.1. United Kingdom
6.2.2. France
6.2.3. Germany
6.2.4. Italy
6.2.5. Spain
6.2.6. Rest Of Europe
6.3. Asia Pacific
6.3.1. India
6.3.2. China
6.3.3. Japan
6.4. Rest Of The World

7. Company Profiles
7.1. Abbott Laboratories Inc
7.2. Alere Inc.
7.3. Ascensia Diabetes Care
7.4. Astrazeneca Ltd
7.5. Bayer AG
7.6. Becton, Dickinson And Company
7.7. Biocon Ltd.
7.8. Boehringer Ingelheim
7.9. Bristol-Myers Squibb
7.10. Cellnovo Group
7.11. Dexcom Inc
7.12. Diamyd Medical
7.13. Eli Lily And Co.
7.14. F. Hoffmann-La Roche Ltd.
7.15. Glaxosmithkline
7.16. Glenmark
7.17. Johnson And Johnson
7.18. Joslin Diabetes Center
7.19. Lifescan
7.20. Lupin Pharmaceuticals Ltd
7.21. Mannkind Corporation
7.22. Medtronic Plc
7.23. Merck & Co.
7.24. Micro Labs Ltd
7.25. Msd Pharmaceuticals
7.26. Novartis
7.27. Novo-Nordisk
7.28. Pfizer
7.29. Prometheon Pharma, Llc
7.30. Sanofi
7.31. Smiths Medical
7.32. Sun Pharmaceuticals Industries Ltd
7.33. Takeda Pharmaceutical Ltd.
7.34. Tandem Diabetes Care
7.35. Thermalin, Inc
7.36. USV Private Limited

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Abbott Laboratories Inc
  • Alere Inc.
  • Ascensia Diabetes Care
  • Astrazeneca Ltd
  • Bayer Ag
  • Becton, Dickinson And Company
  • Biocon Ltd.
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Cellnovo Group
  • Dexcom Inc
  • Diamyd Medical
  • Eli Lily And Co.
  • F. Hoffmann-La Roche Ltd.
  • Glaxosmithkline
  • Glenmark
  • Johnson And Johnson
  • Joslin Diabetes Center
  • Lifescan
  • Lupin Pharmaceuticals Ltd
  • Mannkind Corporation
  • Medtronic Plc
  • Merck & Co.
  • Micro Labs Ltd
  • Msd Pharmaceuticals
  • Novartis
  • Novo-Nordisk
  • Pfizer
  • Prometheon Pharma, Llc
  • Sanofi
  • Smiths Medical
  • Sun Pharmaceuticals Industries Ltd
  • Takeda Pharmaceutical Ltd.
  • Tandem Diabetes Care
  • Thermalin, Inc
  • Usv Private Limited
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll